The study will recruit up to 200 patients with active Crohn's disease or ulcerative colitis and sort them into high- and low-risk cohorts using the PredictSure IBD test.
The project is part of the Human Cell Atlas, an international effort to build reference maps of all human cell types using single-cell analysis.
Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.
Addenbrooke' Hospital will manage and facilitate the fulfillment orders of the firm's PredictSure IBD orders, as well as receive and process all samples.
Inhibiting the associated protein, PAI-1, appeared to ease inflammation and symptoms in a mouse model of inflammatory bowel disease.
Genome- and exome-wide association analysis on inflammatory bowel disease patients with or without thiopurine-induced myelosuppression revealed new and known risk genes.
In PLOS this week: microRNAs linked to brain metastasis risk in lung cancer, effects of Crohn's disease-linked mutation, and more.
The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.
By achieving certification for the assay, called PredictSure IBD, the Cambridge, UK-based firm can sell it for clinical use across Europe.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.